Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Imunon, Inc.IMNN · Entity 8041 | General Counsel and Corp Sec | August 28, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Imunon, Inc.
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,896 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-28 · Grant · Acquired 2,525 · Balance 5,421 F1: Stock granted in lieu of cash for portion of base salary Row 2 · 2026-08-31 · Sale · Disposed 2,525 · Balance 2,896 F2: Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock granted in lieu of cash for portion of base salary
F2: Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 1, 2026 20:06 UTC | Imunon, Inc. IMNN · Entity 8041 | SaleCommon Stock | 2,525 | $1.56 | $3,949.86 |
DisclosureSEC source: 0001437749-26-029405 · rdgdoc.xml · nonDerivative · entry 2 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,896 F2 · price: Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 20:06 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 2,525 | $1.60 | $4,040.00 |
DisclosureSEC source: 0001437749-26-029405 · rdgdoc.xml · nonDerivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,421 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 20:17 UTC | Imunon, Inc. IMNN · Entity 8041 | SaleCommon Stock | 2,449 | $1.63 | $3,992.60 |
DisclosureSEC source: 0001437749-26-028184 · rdgdoc.xml · nonDerivative · entry 2 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,896 F2 · price: Reflects a weighted average sale price of $1.6303 per share, at prices ranging from $1.61 to $1.655 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:17 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 2,449 | $1.65 | $4,040.85 |
DisclosureSEC source: 0001437749-26-028184 · rdgdoc.xml · nonDerivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,345 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 20:13 UTC | Imunon, Inc. IMNN · Entity 8041 | SaleCommon Stock | 2,541 | $1.57 | $3,976.92 |
DisclosureSEC source: 0001437749-26-025661 · rdgdoc.xml · nonDerivative · entry 2 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,896 F2 · price: Reflects a weighted average sale price of $1.5651 per share, at prices ranging from $1.56 to $1.575 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:13 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 2,541 | $1.59 | $4,040.19 |
DisclosureSEC source: 0001437749-26-025661 · rdgdoc.xml · nonDerivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,437 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:15 UTC | Imunon, Inc. IMNN · Entity 8041 | SaleCommon Stock | 2,150 | $1.78 | $3,830.44 |
DisclosureSEC source: 0001437749-26-023948 · rdgdoc.xml · nonDerivative · entry 2 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,896 F2 · price: Reflects a weighted average sale price of $1.7816 per share, at prices ranging from $1.76 to $1.79 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 20:15 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 2,150 | $1.83 | $3,934.50 |
DisclosureSEC source: 0001437749-26-023948 · rdgdoc.xml · nonDerivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,046 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:58 UTC | Imunon, Inc. IMNN · Entity 8041 | SaleCommon Stock | 920 | $1.88 | $1,729.60 |
DisclosureSEC source: 0001437749-26-022944 · rdgdoc.xml · nonDerivative · entry 2 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,896 Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 20:58 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 920 | $1.91 | $1,757.20 |
DisclosureSEC source: 0001437749-26-022944 · rdgdoc.xml · nonDerivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,816 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 20:34 UTC | Imunon, Inc. IMNN · Entity 8041 | SaleCommon Stock | 11,800 | $1.75 | $20,673.60 |
DisclosureSEC source: 0001437749-26-022008 · rdgdoc.xml · nonDerivative · entry 2 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,896 F2 · price: Reflects a weighted average sale price of $1.752 per share, at prices ranging from $1.73 to $1.80 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:34 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 14,696 | $1.72 | $25,277.12 |
DisclosureSEC source: 0001437749-26-022008 · rdgdoc.xml · nonDerivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,696 F1 · shares: Stock granted in lieu of cash for 50% of 2025 annual cash bonus Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:07 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 8,251 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-26-000609 · rdgdoc.xml · derivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,251 Underlying: Common Stock · 8,251 shares Expires 2036-01-02 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:25 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001437749-25-025089 · rdgdoc.xml · derivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417 Underlying: Common Stock · 417 shares Expires 2035-08-04 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:20 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001437749-25-008266 · rdgdoc.xml · derivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2035-03-14 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 20:39 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001437749-24-030886 · rdgdoc.xml · derivative · entry 1 Eylward Susan · CIK 0002039135 · General Counsel and Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-10-07 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows 1/4 on the one year anniversary of the grant and 1/4 on the second, third and fourth year anniversary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.